February 2022

Considerations for Managing TNBC in Older Patients
The management of triple-negative breast cancer (TNBC) is difficult since the disease is characterized by rapid growth, frequent nodal metastases, and a high risk of recurrence. The Young International Society of Geriatric Oncology published a review paper addressing specific considerations for assessing older patients with TNBC and summarizing information on the use of systemic treatments in this age group. Read more.

Advertisement

Safety, Efficacy of Weekly Versus 3-Weekly Docetaxel for MBC
Docetaxel, a taxane chemotherapeutic agent, is the mainstay of treatment for patients with metastatic breast cancer (MBC). Available evidence indicates that the frequency and extent of adverse events associated with docetaxel may be mediated by both the dose and length of treatment. This study helps pharmacists distinguish between the benefits and risks with weekly versus 3-weekly docetaxel. Read more.

PI3K Inhibitor-Induced Hyperglycemia: Avoid Insulin!
The phosphatidylinositol-3-kinase (PI3K) pathway is involved in numerous physiological functions, including cell growth, metabolism, survival, angiogenesis, and glucose metabolism. A recent review paper explored the etiology of hyperglycemia and provided pharmacists with detailed, practical advice recommendations on how to prevent and manage P13K inhibitor–associated hyperglycemia. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App
Advertisement